the activity is similar to darzalex, and seems at first blush to be lower than other BCMA drugs. GSK does have a head start which helps and they are already looking to move into earlier lines of course, but other BCMA drugs do seem to have more activity based on early data. My hunch is the bispecifics will become the preferred (and most commercially successful) drugs in this class when all is said and done
Market Data 
Markets 
AI
